

Registration Opens for SMi's 20th Annual Pain Therapeutics Conference

SMi Reports: Pain Therapeutics will return to London for its 20th consecutive year to explore the cutting-edge research of novel therapeutics

LONDON, UNITED KINGDOM, January 28, 2020 /EINPresswire.com/ -- SMi Group are pleased to announce the 20th annual Pain Therapeutics Conference, taking place in London on 11th – 12th May 2020.

The two-day event will explore the current state of pain treatment, starting with research essentials including choosing the right preclinical models to overviewing clinical success up to date, highlighting cutting-edge research and evaluating the potential of drug candidates in the pipelines of leading pharmaceuticals.

This year, the conference will carry a Pain Research Essentials theme to closely observe analgesics drug development from a preclinical point of view. Industry experts will address the

Pain Therapeutics

Discover cutting-edge research and novel therapeutics in the pipeline

11 - 12 May 2020 | London, UK | www.pain-therapeutics.co.uk

Pain Therapeutics Conference 2020

latest biomarker discoveries, bridging the translational gap, differences of pain pathology across sexes, and consequently, the need for distinct gender animal models. This will be topped with a panel discussion around novel drug targets in neuropathic pain treatment.

Interested parties should register before January 31st 2020 to save £400 from the conference price http://www.pain-therapeutics.co.uk/einpr1

Event Highlights:

- Rethink pain research by exploring novel biomarkers, sex differences in nociception, pain clinical trial design and novel targets.
- Learn about Mundipharma's approach to bridging the translation gap in analgesic drug development.
- Gain understanding of Grunenthal's rationale behind targeting the NOP receptor for chronic pain treatment.
- Explore struggles of opioid-based treatments and explore targeting non-opioid alternatives such as cannabinoids from Centrexion.
- Improve your understanding of the role of neuro-immune interactions in pain with GSK.

Confirmed Speakers:

- Richard Malamut, Chief Medical Officer and EVP, Collegium Pharma
- Edward Emery, Investigator, GSK
- Carole Torsney, Senior Lecturer, University of Edinburgh
- James Campbell, Chief Scientific Officer, Centrexion Therapeutics
- Theo Meert, Head of R&D Global Governmental Grant Office, Janssen
- Zahid Ali, Head Clinical Pharmacology and Translational Medicine, Mundipharma Research Limited
- Domenico Merante, Clinical Development Expert, Independent
- Tanja Ouimet, Director of Clinical Development, Pharmaleads
- Stephen Hunt, Professor, UCL
- Cristina Cosi, Senior Scientist Pharmacology, CNS Innovation Unit, Pierre-Fabre Research Institute
- Sandrine Geranton, Associate Professor, UCL
- Joop van Griensven, President, Pain Alliance Europe

The full agenda and speaker line-up can be viewed online at http://www.pain-therapeutics.co.uk/einpr1

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk

Pain Therapeutics 2020

Conference: 11th – 12th May 2020 Copthorne Tara Hotel, London, UK http://www.pain-therapeutics.co.uk/einpr1 #SMiPain

--- ENDS -

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal SMi Group +442078276000 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.